POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as Part of Eubiologics’ COVID-19 Vaccine Candidate, EuCorVac-19

POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as Part of Eubiologics’ COVID-19 Vaccine Candidate, EuCorVac-19

Post Views: 95 POP Biotechnologies (POP BIO), a biopharmaceutical startup, announces the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19…